@Article{biocell.2022.022021,
AUTHOR = {NINGYU LI, XIAOFANG CHEN, SUXIA GENG, PEILONG LAI, LISI HUANG, MINMING LI, XIN HUANG, CHENGXIN DENG, YULIAN WANG, JIANYU WENG, XIN DU},
TITLE = {<i>miR-103-3p</i> regulates the differentiation of bone marrow mesenchymal stem cells in myelodysplastic syndrome},
JOURNAL = {BIOCELL},
VOLUME = {47},
YEAR = {2023},
NUMBER = {1},
PAGES = {133--141},
URL = {http://www.techscience.com/biocell/v47n1/49927},
ISSN = {1667-5746},
ABSTRACT = {The pathogenesis of myelodysplastic syndrome (MDS) may be related to the abnormal expression of microRNAs
(miRNAs), which could influence the differentiation capacity of mesenchymal stem cells (MSCs) towards adipogenic and
osteogenic lineages. In this study, exosomes from bone marrow plasma were successfully extracted and identified.
Assessment of <i>miR-103-3p</i> expression in exosomes isolated from BM in 34 MDS patients and 10 controls revealed its
0.52-fold downregulation in patients with MDS compared with controls (NOR) and was downregulated 0.55-fold in
MDS-MSCs compared with NOR-MSCs. Transfection of MDS-MSCs with the <i>miR-103-3p</i> mimic improved osteogenic
differentiation and decreased adipogenic differentiation in vitro, while inhibition of <i>miR-103-3p</i> showed the opposite
results in NOR-MSCs. Thus, the expression of <i>miR-103-3p</i> decreases in MDS BM plasma and MDS-MSCs, significantly
impacting MDS-MSCs differentiation. The <i>miR-103-3p</i> mimics may boost MDS-MSCs osteogenic differentiation while
weakening lipid differentiation, thereby providing possible target for the treatment of MDS pathogenesis.},
DOI = {10.32604/biocell.2022.022021}
}